05/28/2026
Merck has launched the MALBEC clinical trial to evaluate MK-8748 (Tiespectus) for neovascular (wet) age-related macular degeneration. The study will explore a new approach aimed at supporting vascular stability in the retina. Learn more: https://brnw.ch/21x2TX0
MALBEC (NCT07440225) is a randomized, double-masked trial evaluating the safety and efficacy of MK-8748 at 2 dose levels versus control (aflibercept 2mg).